CogniScreen utilizes an AI-driven platform to analyze electronic health record data, providing precise cognitive scores across various dementia types and stages. This technology enhances patient selection for clinical trials, increasing screen positivity rates beyond the national average and streamlining recruitment processes.
Funding
Funding not disclosed
Founders
Product
Problem
Recruiting suitable patients for dementia clinical trials is challenging due to low screen positivity rates and the need for extensive cognitive testing. Traditional methods often miss patients with co-occurring dementias, leading to inefficient recruitment processes and wasted resources.
Solution
CogniScreen offers an AI-powered platform that analyzes existing electronic health record (EHR) data to provide quantitative cognitive scores across various dementia types and stages. The platform identifies potential clinical trial participants by evaluating cognitive health without requiring additional tests or complex procedures. By leveraging comprehensive analysis of cognitive functions, including the ability to detect co-occurring dementias, CogniScreen improves screen positivity rates, expands the patient pipeline, and streamlines the recruitment process for dementia clinical trials. The platform integrates with leading EHRs, using available data to accelerate screening.
Target Audience
CogniScreen's primary customers are clinical trial sponsors and research organizations focused on dementia therapeutics, as well as healthcare providers seeking to improve early detection and diagnosis of dementia.
Features
- AI-driven analysis of EHR data for cognitive assessment
- Quantitative cognitive scores across various dementia types and stages
- Detection of co-occurring dementias
- Improved screen positivity rates compared to national average
- Expanded clinical trial patient pipeline through augmented pre-screening
- Seamless integration with leading EHR systems